×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| SEQUENT SCIENTIFIC LTD. | 525.5 | 33.7 | 410.7 | 0.13 | 4,684 | 155.0 |
| AARTI DRUGS LTD. | 5213.4 | 486.4 | 5209.6 | 5.33 | 4521 | 24.0 |
| Dishman Carbogen Amcis Limited | 1002.8 | 26.7 | 628.6 | 0.17 | 4418 | 37.2 |
Sequent Scientific Limited, with Security Code 512529, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46.6 | 40.4 | 49.1 | 42.2 | 36.8 | 57.7 | 42.0 | 36.3 | 42.3 | 41.1 |
| Expenses | 52.6 | 49.5 | 56.8 | 46.4 | 42.5 | 59.7 | 44.1 | 40.8 | 45.1 | 43.1 |
| Operating Profit | -6.0 | -9.1 | -7.7 | -4.2 | -5.7 | -2.0 | -2.1 | -4.5 | -2.8 | -2.0 |
| OPM % | -12.97% | -22.43% | -15.68% | -9.85% | -15.61% | -3.43% | -5% | -12.35% | -6.57% | -4.97% |
| Other Income | 8.0 | 3.4 | 9.9 | 13.4 | 13.0 | 10.8 | 11.6 | 11.6 | 12.0 | 10.2 |
| Interest | 0.9 | 1.0 | 1.2 | 1.1 | 1.0 | 0.8 | 1.0 | 1.2 | 1.0 | 1.1 |
| Depreciation | 2.3 | 2.4 | 2.4 | 2.1 | 2.1 | 2.0 | 2.1 | 2.2 | 2.3 | 2.3 |
| Profit before tax | -1.2 | -2.8 | -1.4 | 6.1 | 4.1 | 6.1 | 10.7 | 4.0 | 6.2 | 6.0 |
| Tax % | 33.7% | -24.7% | -34.2% | -24.8% | -8.2% | 25.6% | -33.5% | -23.6% | -27.1% | 29.5% |
| Net Profit | -1.6 | -6.8 | -0.9 | 4.6 | 3.8 | 4.5 | 4.3 | 2.8 | 4.2 | 3.4 |
| EPS in Rs | -0.07 | -0.27 | -0.04 | 0.18 | 0.15 | 0.18 | 0.17 | 0.11 | 0 | 0.13 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 375.3 | 366.7 | 333.2 | 346.0 | 329.4 | 361.2 | 390.2 | 368.7 | 390.8 | 401.7 |
| Expenses | 365.0 | 370.0 | 341.4 | 330.8 | 307.1 | 328.9 | 348.3 | 329.6 | 356.3 | 355.5 |
| Operating Profit | 10.3 | -3.4 | -8.2 | 15.1 | 22.2 | 32.3 | 42.0 | 39.1 | 34.5 | 46.3 |
| OPM % | 2.75% | -0.92% | -2.47% | 4.37% | 6.76% | 8.93% | 10.75% | 10.61% | 8.83% | 11.51% |
| Other Income | 2.9 | -59.9 | -22.7 | 9.7 | 7.3 | -0.7 | 2.7 | 0.2 | 5.5 | 1.3 |
| Interest | 9.7 | 10.9 | 10.5 | 12.6 | 12.6 | 12.4 | 16.4 | 14.3 | 15.0 | 15.1 |
| Depreciation | 13.7 | 14.7 | 14.2 | 15.4 | 15.5 | 16.5 | 16.3 | 17.1 | 17.0 | 16.1 |
| Profit before tax | -10.2 | -27.2 | -32.2 | -11.2 | -1.3 | 7.3 | 12.0 | 12.2 | 8.4 | 16.7 |
| Tax % | -4.1% | 4.1% | -37.7% | 122.4% | 616% | -51.7% | -24.5% | 19.7% | 20% | -36.2% |
| Net Profit | -9.8 | -92.4 | -34.7 | -6.9 | 10.7 | 1.3 | 9.1 | 6.3 | 6.5 | 10.4 |
| EPS in Rs | -0.36 | -3.77 | -1.4 | -0.34 | 0.33 | 0.04 | 0.26 | 0.1 | 0.13 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | -5% |
| 3 Years: | -7% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -2% |
| 3 Years: | 9% |
| TTM: | 736% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| 1 Year: | 64% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 6% |
| 3 Years: | 3% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 46% |
| 5 Years: | -20% |
| 3 Years: | -18% |
| TTM: | 206% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| 1 Year: | 64% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|